Amneal Reports Positive Phase 4 ELEVATE-PD Results for CREXONT
BRIDGEWATER, N.J., June 5, 2026 Amneal Pharmaceuticals announced positive interim results from the ongoing Phase 4 ELEVATE-PD study, demonstrating...
Parkinson’s Disease
Advertisement
Merz Therapeutics Unveils New Insights Into Parkinson’s OFF Episodes at WPC 2026
FRANKFURT, Germany & RALEIGH, N.C. — May 28, 2026 Merz Therapeutics presented new research at the World Parkinson Congress...
TreeFrog’s TFG-001 Shows Strong Parkinson’s Recovery Data
BORDEAUX, France, May 25, 2026 TreeFrog Therapeutics announced new preclinical data showing that its investigational 3D neural microtissue cell...
Biogen, Denali End BIIB122 Parkinson’s Program
CAMBRIDGE, Massachusetts and SOUTH SAN FRANCISCO, California, May 21, 2026 Biogen Inc. and Denali Therapeutics Inc. announced that the...
AndzonBio2 and Cambridge Partner on Neuroinflammation Therapies
PARIS and CAMBRIDGE, UK, May 13, 2026 AndzonBio2 announced a strategic collaboration with the ALBORADA Drug Discovery Institute (ADDI)...
Advertisements
XellSmart Advances Phase 2 Parkinson’s Cell Therapy Trial
Suzhou, China | April 14, 2026 XellSmart has announced the initiation of a multicenter Phase II clinical trial evaluating...
XellSmart Secures Dual FDA, NMPA IND for MSA-P
SUZHOU, China, March 2, 2026 XellSmart Pharmaceutical Co., Ltd. announced that it has received its fourth consecutive Investigational New...
Parkinson’s IQ + You Empowers Nevada Patients
February 24, 2026 – New York, USA The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has announced that...
Jupiter Neurosciences Aligns Capital With Clinical Growth
JUPITER, Fla., Feb. 23, 2026 — Jupiter Neurosciences, a clinical-stage pharmaceutical company focused on neuroinflammation and central nervous system...
Single-Molecule Proteomics Targets Alpha-Synuclein in Parkinson’s
January 28, 2026 — Nautilus Biotechnology, Weill Cornell Medicine–Qatar (WCM-Q), and The Michael J. Fox Foundation (MJFF) have launched...
Advertisement
